A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Bazlitoran (Primary)
  • Indications Dermatomyositis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIONEER
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2018 According to an Idera Pharmaceuticals media release, the company plans to report top-line data from this study by the end of the 2nd quarter of 2018.
    • 06 Nov 2017 According to an Idera Pharmaceuticals Inc. media release, clinical data results from this trial are expected in the second quarter of 2018.
    • 10 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top